Biomedical Research

Objective: To evaluate the efficacy and safety of the treatment of refractory atopic dermatitis with dust mite allergen vaccine through sublingual immunotherapy.

Methods: To adopt the self control research, compare the eczema area and severity index (EASI), percentage of skin damage area (BSA%) and change in pruritus scoring and drug use scoring of 35 patients with dust mite allergen and refractory atopic dermatitis after receiving the treatment with dust mite allergen vaccine and sublingual immunotherapy for 1 year, and observe recurrence.

Results: 31 patients insist in completing the course of treatment for 1 year and 4 patients quit. Eczema area and severity index (EASI), percentage of skin damage area (BSA%) and change in pruritus scoring and drug use scoring after treatment obviously reduce (P mean<0.01) compared with those before treatment. The effective rate is 77.41%. Adverse reactions related to treatment do not obviously occur. The recurrence rate is 9.67% after 1-year follow-up.

Conclusion: The sublingual allergen immunotherapy is an effective method with good safety to treat refractory atopic dermatitis caused by dust mite.

Author(s): Haiyun Shi, Yan Zhuang, Xueyan Wang
Abstract | Full-Text | PDF

Share this